E. Merck KG operates as a general partner for Merck KGaA, which develops, manufactures, and distributes pharmaceutical products. The company is based in Darmstadt, Germany.
Frankfurter Strasse 250
E. Merck KG Announces Board Appointments, Effective April 30, 2016
Jan 22 16
E. Merck KG has named Udit Batra, currently head of the life science business sector, and Walter Galinat, currently head of the performance materials business sector, as new members to its executive board, effective April 30, 2016. Bernd Reckmann, currently the Executive Board member responsible for Life Science and Performance Materials, will retire on conclusion of the Annual General Meeting on April 29, 2016. Prior to joining Merck KGaA, Darmstadt, Germany, Batra worked for Novartis as Head of Global Public Health and Market Access for Vaccines and Diagnostics, as Global Head of Corporate Strategy, and as Country President of the pharmaceutical business in Australia.
E. Merck KG Announces Management Changes, Effective January 1, 2015
Sep 18 14
Merck KGaA announced E. Merck KG has appointed Stefan Oschmann to the position of Vice Chairman and Deputy CEO. Concurrently, Bel n Garijo has been appointed to the Executive Board to take over leadership for the Pharma business. The management changes will be effective as of January 1, 2015. Oschmann, currently CEO Pharma, will represent Karl-Ludwig Kley, Chief Executive Officer and Chairman of the Executive Board, in hisresponsibilities. Both will share strategic management functions and represent the company with politicians and international organizations. As a member of the Executive Board, Garijo, currently CEO of Merck's biopharmaceutical division Merck Serono, will assume responsibility for the whole Pharma business, which in addition to Merck Serono comprisesConsumer Health, Allergy and Biosimilars.